このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparison of the Effects of Two Different Home Exercise Programs on Femoral Cartilage Thickness and Clinical Parameters in Individuals With Knee Osteoarthritis: A Randomized Controlled Trial

2026年6月14日 更新者:MERVE ARBAY、Pamukkale University

Knee osteoarthritis (OA) is one of the most common joint disorders worldwide and is a leading cause of pain, limited mobility, and functional disability, particularly in the elderly population (1). According to 2020 data, approximately 654 million individuals aged 40 years and older are affected by knee OA worldwide, with a global prevalence of 22.9% in this age group (2). In our country as well, OA is reported as the second most common rheumatologic disease. The disease not only negatively affects individuals' quality of life but also creates a significant socioeconomic burden through work loss, hospital admissions, and the need for surgical interventions (3).

The pathogenesis of knee OA is a complex process involving articular cartilage degeneration, subchondral bone sclerosis, synovial tissue proliferation, and osteophyte formation. Once cartilage damage begins, its capacity for spontaneous healing is extremely limited; therefore, early interventions aimed at slowing or halting disease progression are of critical importance (4,5). In this context, non-pharmacological interventions, particularly exercise programs that may contribute to maintaining cartilage integrity, are strongly recommended as first-line treatment options in current clinical guidelines (6-8).

The beneficial effects of exercise therapy on pain and function in patients with knee OA are well documented. However, the structural effects of exercise on femoral cartilage thickness have been relatively less investigated. Tuna et al. evaluated femoral cartilage thickness using ultrasonography in 40 patients with knee OA following a 12-week quadriceps strengthening program and reported statistically significant increases in cartilage thickness in the medial condyle, lateral condyle, and intercondylar region at 3 months (9). This pioneering study suggests that muscle strengthening programs may have not only symptomatic but also structural benefits. Similarly, Bozan et al. reported a strong positive correlation between quadriceps muscle thickness (rectus femoris + vastus intermedius) and femoral cartilage thickness, supporting the idea that muscle loss parallels cartilage degeneration (10). However, these studies focused exclusively on the quadriceps muscle, and the effects of hip musculature on femoral cartilage thickness have not been investigated. Recent biomechanical studies indicate that hip abductor and adductor muscles play a critical role in knee joint loading patterns.

Hip abductor muscles provide pelvic stability during gait and directly influence knee adduction moments. Weakness of the gluteus medius leads to contralateral pelvic drop, increasing medial compartment loading on the ipsilateral knee and accelerating medial tibiofemoral cartilage wear (11-14). Indeed, Segal et al., using data from the Multicenter Osteoarthritis Study (MOST), demonstrated via MRI that greater hip abductor strength significantly reduces the risk of progression of medial patellofemoral and lateral tibiofemoral cartilage damage (15). On the other hand, hip adductor muscles are also thought to contribute to knee adduction moments by eccentrically controlling femoral varus motion; however, this relationship has been studied far less compared to quadriceps and abductors (13,16-18).

Systematic reviews and meta-analyses have shown that individuals with knee OA have up to 24% lower isometric hip abductor strength compared to healthy controls (13,14,19). Randomized controlled trials investigating combined hip and quadriceps strengthening programs have reported significant improvements in pain and function. However, none of these studies have used femoral cartilage thickness measured by ultrasonography as a primary outcome.

A review of the current literature reveals that although studies exist examining the effects of quadriceps strengthening on femoral cartilage thickness, no randomized controlled trial has compared hip abductor and adductor strengthening exercises with a quadriceps strengthening program, using ultrasonographic femoral cartilage thickness as the primary outcome measure. This study aims to address this gap. All interventions will be applied as non-invasive home exercise programs, and all measurements will be performed using ultrasonography. Baseline, 1-month, and 3-month assessments will also allow evaluation of the temporal effects of exercise on cartilage structure. The findings are expected to provide scientific evidence regarding the structural protective effects of hip exercises in knee OA rehabilitation and serve as pilot data for future large-scale multicenter studies.

The aim of this study is to compare patients with knee OA receiving quadriceps strengthening exercises alone with those receiving additional hip abductor/adductor strengthening exercises in terms of changes in femoral cartilage thickness, and to evaluate whether there is a correlation between femoral cartilage thickness and the thickness of the rectus femoris, gluteus medius,

調査の概要

研究の種類

介入

入学 (推定)

56

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Kütahya、トルコ(Türkiye)
        • Kütahya Physical Therapy and Rehabilitation Hospital
        • コンタクト:
        • 副調査官:
          • Hasan Celtek

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Age ≥18 years
  2. Diagnosis of knee osteoarthritis according to ACR criteria, Kellgren-Lawrence grade 2-3
  3. Knee pain for at least 3 months
  4. Having the physical capacity to perform a home exercise program
  5. Willingness to provide written informed consent

Exclusion Criteria:

  1. History of knee, hip, or spine surgery
  2. Active inflammatory arthritis (e.g., rheumatoid arthritis, gout, psoriatic arthritis)
  3. Intra-articular injection within the last 3 months
  4. Neurological or neuromuscular disorders
  5. Body mass index (BMI) > 40 kg/m²
  6. Pregnancy
  7. Cardiovascular or orthopedic contraindications preventing participation in a regular exercise program
  8. Cognitive impairment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Quadriceps Plus Hip Strengthening Group

For 3 months, 3 days per week, participants will perform quadriceps strengthening exercises combined with hip abductor and adductor strengthening exercises.

In addition to all exercises included in the Quadriceps Strengthening Group, participants will perform:

Hip abduction (side-lying position with ankle weights) Clamshell exercise (for gluteus medius activation) Hip adduction (supine position with isometric contraction using a pillow) Side-lying hip abduction with a resistance band

quadriceps strengthening exercises combined with hip abductor and adductor strengthening exercises
アクティブコンパレータ:Quadriceps Strengthening Group

For 3 months, 3 days per week, participants will perform a quadriceps strengthening exercise program only.

The program will include:

Knee extension (in a seated position, with and without resistance) Terminal knee extension Straight leg raise Mini squat (0-30° knee flexion)

quadriceps strengthening exercise program

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Medial femoral condyle cartilage thickness (mm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
All ultrasonographic measurements will be performed using a Clarius L7 HD3 linear high-frequency transducer (7.5-12 MHz) with the knee positioned in 90° flexion in a standardized manner. Three measurements will be obtained at each anatomical location, and the mean value will be recorded for analysis.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).

二次結果の測定

結果測定
メジャーの説明
時間枠
Lateral femoral condyle cartilage thickness (mm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
All ultrasonographic measurements will be performed using a Clarius L7 HD3 linear high-frequency transducer (7.5-12 MHz) with the knee positioned in 90° flexion in a standardized manner. Three measurements will be obtained at each anatomical location, and the mean value will be recorded for analysis.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Intercondylar area cartilage thickness (mm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
All ultrasonographic measurements will be performed using a Clarius L7 HD3 linear high-frequency transducer (7.5-12 MHz) with the knee positioned in 90° flexion in a standardized manner. Three measurements will be obtained at each anatomical location, and the mean value will be recorded for analysis.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Ultrasound Femoral Cartilage Degeneration Grade
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).

Evaluation will be performed with the symptomatic knee positioned in maximum flexion.

Cartilage degeneration will be classified as follows:

Grade 1: Blurred margins or partial loss of sharpness without thickness change Grade 2: Blurred margin space with partial loss of sharpness without thickness change Grade 3: Blurred margins with loss of clarity Grade 4: Poorly defined margins with a completely opaque band Grade 5: Evident thickness alteration Grade 6: Cartilage band cannot be visualized

Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Synovial Hypertrophy Grade
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).

Ultrasound assessment will be performed in accordance with the EULAR and Outcome Measures in Rheumatology Clinical Trials (OMERACT) guidelines using both longitudinal and axial views.

For evaluation of synovial hypertrophy, the suprapatellar, medial parapatellar, and lateral parapatellar recesses will be scanned with the knee positioned in 30° flexion.

Synovial hypertrophy will be graded as follows:

Grade 0: No synovial thickening Grade 1: Mild synovial thickening Grade 2: Moderate synovial thickening Grade 3: Severe synovial thickening

Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Rectus femoris muscle thickness (cm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Rectus femoris muscle thickness will be measured with the participant in the supine position and with the hip and knee in extension. The ultrasound transducer will be placed axially over the muscle. Measurements will be obtained at the junction between the lower one-third and upper two-thirds of the distance from the anterior superior iliac spine (ASIS) to the superior pole of the patella, which will serve as the anatomical reference point.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Gluteus medius (GMed) muscle thickness (cm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Participants will be positioned in side-lying with the left leg uppermost. The left hip region will be exposed, and a towel will be placed under the ankle to maintain a neutral alignment of the hip, knee, and ankle joints. To assess the gluteus medius muscle, the ultrasound transducer will be placed longitudinally on the lateral aspect of the hip, just superior to the greater trochanter, at the anterior one-quarter of the line connecting the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS).
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Adductor longus muscle thickness (cm)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Participants will be positioned in the supine position, with the thigh in abduction and external rotation and the knee flexed to 20-30°. The knee will be supported with a rolled towel. Measurements will be obtained at the junction between the upper one-third and lower two-thirds of the distance from the pubic symphysis to the medial femoral epicondyle, which will serve as the anatomical reference point.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
Visual Analog Scale (VAS)
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
The Visual Analog Scale is used to assess pain intensity. Participants will be asked to indicate the severity of their knee pain on a scale ranging from 0 (no pain) to 10 (worst imaginable pain) by selecting the point that best represents their pain level.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
WOMAC Osteoarthritis Index
時間枠:Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).
The WOMAC Osteoarthritis Index consists of 24 items rated on a 5-point Likert scale. It includes three subscales: pain, stiffness, and physical function. The pain subscale contains 5 items and is scored from 0 to 20. The stiffness subscale includes 2 items and is scored from 0 to 8. The physical function subscale consists of 17 items and is scored from 0 to 68. Higher scores indicate greater pain, increased stiffness, and poorer functional status. The Turkish validity and reliability study of the WOMAC scale was conducted by Tüzün et al.
Participants receiving treatment will be evaluated at baseline (T0), at Month 1 (T1), and at Month 3 (T2).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月20日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2027年7月1日

試験登録日

最初に提出

2026年6月14日

QC基準を満たした最初の提出物

2026年6月14日

最初の投稿 (実際)

2026年6月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月18日

QC基準を満たした最後の更新が送信されました

2026年6月14日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する